Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase C01.034: cathepsin S

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Inhibitors Pharma

(References are filtered for relevance to Inhibitor. To remove the filter click here. See explanation.)

    2025
  1. Bentley,D., Mannino,M., Manchester,M., Teixeira,P.C., Reis,B., Boyce,M. and Nagel,S.
    A randomized, double-blind, placebo-controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease
    Clin Transl Sci (2025) 18, e13901-e13901. PubMed  Europe PubMed DOI  PMC  EPMC  I
  2. Previti,S., Iraci,N., Calcaterra,E., Ettari,R. and Zappala,M.
    A Second Opportunity for the Peptide-Based Analogues with gamma-Lactam at the P1 Position: Human Cathepsin S Inhibition
    Pharmaceuticals (Basel) (2025) 18 PubMed  Europe PubMed DOI  PMC  EPMC  I
  3. Yang,C., Fu,L., Li,R., Tang,H., Chen,Z., Gan,S., Sun,J., Li,S., Li,J. and Yao,L.
    Cathepsin S mediates the disruption of airway epithelial Pannexin 1 via an Akt-dependent pathway in an LPS-induced murine model of acute lung injury
    Exp Cell Res (2025) 450, 114663-114663. PubMed  Europe PubMed DOI  I
    4. 2024
  4. Zhang,Y., Yang,L., Gan,Y., Zhao,C., Zhou,C., Chen,J., Yin,Y., Xia,S., Yang,H., Bao,X., Zhang,M., Xu,Y. and Li,J.
    Benzydamine attenuates microglia-mediated neuroinflammation and ischemic brain injury by targeting cathepsin s
    Int Immunopharmacol (2024) 146, 113824-113824. PubMed  Europe PubMed DOI  I
    5. 2023
  5. Abdoli,M., Krasniqi,V., Bonardi,A., Gutschow,M., Supuran,C.T. and Zalubovskis,R.
    4-Cyanamido-substituted benzenesulfonamides act as dual carbonic anhydrase and cathepsin inhibitors
    Bioorg Chem (2023) 139, 106725-106725. PubMed  Europe PubMed DOI  I
  6. Fuchs,N., Meta,M., Lantzberg,B., Bros,M., Ling Kuan,S., Weil,T. and Schirmeister,T.
    Subnanomolar Cathepsin S Inhibitors with High Selectivity: Optimizing Covalent Reversible alpha-Fluorovinylsulfones and alpha-Sulfonates as Potential Immunomodulators in Cancer
    ChemMedChem (2023) 18, e202300160-e202300160. PubMed  Europe PubMed DOI  I
  7. Huang,H., Zhang,Y., Xu,X., Liu,Y., Zhao,J., Ma,L., Lei,J., Ge,W., Li,N., Ma,E., Li,Y. and Yuan,L.
    Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer cells
    Bioorg Med Chem Lett (2023) 80, 129087-129087. PubMed  Europe PubMed DOI  I
    8. 2021
  8. Oldak,L., Sankiewicz,A., Zelazowska-Rutkowska,B., Cylwik,B., Lukaszewski,Z., Skoczylas,M. and Gorodkiewicz,E.
    Two SPRi biosensors for the determination of cathepsin S in blood plasma
    Talanta (2021) 225, 121900-121900. PubMed  Europe PubMed DOI  I
    9. 2020
  9. Ahmad,S., Bhagwati,S., Kumar,S., Banerjee,D. and Siddiqi,M.I.
    Molecular modeling assisted identification and biological evaluation of potent cathepsin S inhibitors
    J Mol Graph Model (2020) 96, 107512-107512. PubMed  Europe PubMed DOI  I
  10. Cianni,L., Rocho,F.D.R., Rosini,F., Bonatto,V., Ribeiro,J.F.R., Lameira,J., Leitao,A., Shamim,A. and Montanari,C.A.
    Optimization strategy of single-digit nanomolar cross-class inhibitors of mammalian and protozoa cysteine proteases
    Bioorg Chem (2020) 101, 104039-104039. PubMed  Europe PubMed DOI  I
  11. Lai,C.H., Chang,J.Y., Wang,K.C., Lee,F.T., Wu,H.L. and Cheng,T.L.
    Pharmacological inhibition of cathepsin S suppresses abdominal aortic aneurysm in mice
    Eur J Vasc Endovasc Surg (2020) PubMed  Europe PubMed DOI  U  I
  12. Lemke,C., Cianni,L., Feldmann,C., Gilberg,E., Yin,J., Dos Reis Rocho,F., De Vita,D., Bartz,U., Bajorath,J., Montanari,C.A. and Gutschow,M.
    N-Sulfonyl dipeptide nitriles as inhibitors of human cathepsin S: In silico design, synthesis and biochemical characterization
    Bioorg Med Chem Lett (2020) 30, 127420-127420. PubMed  Europe PubMed DOI  I
  13. van Dalen,F.J., Bakkum,T., Van Leeuwen,T., Groenewold,M., Deu,E., Koster,A.J., van Kasteren,S.I. and Verdoes,M.
    Application of a Highly Selective Cathepsin S Two-step Activity-Based Probe in Multicolor Bio-Orthogonal Correlative Light-Electron Microscopy
    Front Chem (2020) 8, 628433-628433. PubMed  Europe PubMed DOI  PMC  EPMC  I
    14. 2019
  14. Chaput,L., Selwa,E., Elisee,E. and Iorga,B.I.
    Blinded evaluation of cathepsin S inhibitors from the D3RGC3 dataset using molecular docking and free energy calculations
    J Comput Aided Mol Des (2019) 33, 93-103. PubMed  Europe PubMed DOI  I
  15. He,X., Man,V.H., Ji,B., Xie,X.Q. and Wang,J.
    Calculate protein-ligand binding affinities with the extended linear interaction energy method: application on the cathepsin S set in the D3R Grand Challenge 3
    J Comput Aided Mol Des (2019) 33, 105-117. PubMed  Europe PubMed DOI  I
  16. Klinngam,W., Janga,S.R., Lee,C., Ju,Y., Yarber,F., Shah,M., Guo,H., Wang,D., MacKay,J.A., Edman,M.C. and Hamm-Alvarez,S.F.
    Inhibition of cathepsin S reduces lacrimal gland inflammation and increases tear flow in a mouse model of Sjogren's syndrome
    Sci Rep (2019) 9, 9559-9559. PubMed  Europe PubMed DOI  I
  17. Shockey,W.A., Kieslich,C.A., Wilder,C.L., Watson,V. and Platt,M.O.
    Dynamic model of protease state and inhibitor trafficking to predict protease activity in breast cancer cells
    Cell Mol Bioeng (2019) 12, 275-288. PubMed  Europe PubMed DOI  PMC  EPMC  I
  18. Small,D.M., Brown,R.R., Doherty,D.F., Abladey,A., Zhou-Suckow,Z., Delaney,R.J., Kerrigan,L., Dougan,C.M., Borensztajn,K.S., Holsinger,L., Booth,R., Scott,C.J., Lopez-Campos,G., Elborn,J.S., Mall,M.A., Weldon,S. and Taggart,C.C.
    Targeting of cathepsin S reduces cystic fibrosis-like lung disease
    Eur Respir J (2019) 53, 1801523-1801523. PubMed  Europe PubMed DOI  K  I
    19. 2018
  19. Chen,C.Y., Chen,C.Y., Liu,C.C. and Chen,C.P.
    Omega-3 polyunsaturated fatty acids reduce preterm labor by inhibiting trophoblast cathepsin S and inflammasome activation
    Clin Sci (Lond) (2018) 132, 2221-2239. PubMed  Europe PubMed DOI  I
  20. Kubo,K., Kawato,Y., Nakamura,K., Nakajima,Y., Nakagawa,T.Y., Hanaoka,K., Oshima,S., Fukahori,H., Inami,M., Morokata,T. and Higashi,Y.
    Effective suppression of donor specific antibody production by cathepsin S inhibitors in a mouse transplantation model
    Eur J Pharmacol (2018) 838, 145-152. PubMed  Europe PubMed DOI  I
  21. Tber,Z., Wartenberg,M., Jacques,J.E., Roy,V., Lecaille,F., Warszycki,D., Bojarski,A.J., Lalmanach,G. and Agrofoglio,L.A.
    Selective inhibition of human cathepsin S by 2,4,6-trisubstituted 1,3,5-triazine analogs
    Bioorg Med Chem (2018) 26, 4310-4319. PubMed  Europe PubMed DOI  I
  22. Yuan,L., Sheng,L., He,W., Zou,C., Hu,B., Liu,J., Ge,W., Liu,Y., Wang,J. and Ma,E.
    Discovery of novel cathepsin inhibitors with potent anti-metastatic effects in breast cancer cells
    Bioorg Chem (2018) 81, 672-680. PubMed  Europe PubMed DOI  I
    23. 2017
  23. Ahmad,S. and Siddiqi,M.I.
    Insights from molecular modeling into the selective inhibition of cathepsin S by its inhibitor
    J Mol Model (2017) 23, 92-92. PubMed  Europe PubMed DOI  I
  24. Galibert,M., Wartenberg,M., Lecaille,F., Saidi,A., Mavel,S., Joulin-Giet,A., Korkmaz,B., Bromme,D., Aucagne,V., Delmas,A.F. and Lalmanach,G.
    Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S
    Eur J Med Chem (2017) 144, 201-210. PubMed  Europe PubMed DOI  I
  25. Hsieh,M.J., Lin,C.W., Chen,M.K., Chien,S.Y., Lo,Y.S., Chuang,Y.C., Hsi,Y.T., Lin,C.C., Chen,J.C. and Yang,S.F.
    Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
    Sci Rep (2017) 7, 45039-45039. PubMed  Europe PubMed DOI  I
  26. Tato,M., Kumar,S.V., Liu,Y., Mulay,S.R., Moll,S., Popper,B., Eberhard,J.N., Thomasova,D., Rufer,A.C., Gruner,S., Haap,W., Hartmann,G. and Anders,H.J.
    Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury
    Sci Rep (2017) 7, 2775-2775. PubMed  Europe PubMed DOI  PMC  EPMC  I
  27. Thanei,S., Theron,M., Silva,A.P., Reis,B., Branco,L., Schirmbeck,L., Kolb,F.A., Haap,W., Schindler,T. and Trendelenburg,M.
    Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages
    Biochem Pharmacol (2017) 146, 151-164. PubMed  Europe PubMed DOI  I
  28. Yan,X., Wu,C., Chen,T., Santos,M.M., Liu,C.L., Yang,C., Zhang,L., Ren,J., Liao,S., Guo,H., Sukhova,G.K. and Shi,G.P.
    Cathepsin S inhibition changes regulatory T-cell activity in regulating bladder cancer and immune cell proliferation and apoptosis
    Mol Immunol (2017) 82, 66-74. PubMed  Europe PubMed DOI  I
    29. 2016
  29. Hewitt,E., Pitcher,T., Rizoska,B., Tunblad,K., Henderson,I., Sahlberg,B.L., Grabowska,U., Classon,B., Edenius,C., Malcangio,M. and Lindstrom,E.
    Selective cathepsin S inhibition with MIV-247 attenuates mechanical allodynia and enhances the antiallodynic effects of gabapentin and pregabalin in a mouse model of neuropathic pain
    J Pharmacol Exp Ther (2016) 358, 387-396. PubMed  Europe PubMed DOI  I
  30. Huang,C.C., Lee,C.C., Lin,H.H. and Chang,J.Y.
    Cathepsin S attenuates endosomal EGFR signalling: a mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors
    Sci Rep (2016) 6, 29256-29256. PubMed  Europe PubMed DOI  PMC  EPMC  I
  31. Ihmaid,S.K., Ahmed,H.E., Zayed,M.F. and Abadleh,M.M.
    Self organizing map-based classification of cathepsin K and S inhibitors with different selectivity profiles using different structural molecular fingerprints: design and application for discovery of novel hits
    Molecules (2016) 21, 175-175. PubMed  Europe PubMed DOI  I
  32. Plebanek,E., Chevrier,F., Roy,V., Garenne,T., Lecaille,F., Warszycki,D., Bojarski,A.J., Lalmanach,G. and Agrofoglio,L.A.
    Straightforward synthesis of 2,4,6-trisubstituted 1,3,5-triazine compounds targeting cysteine cathepsins K and S
    Eur J Med Chem (2016) 121, 12-20. PubMed  Europe PubMed DOI  I
  33. Wilkinson,R.D., Young,A., Burden,R.E., Williams,R. and Scott,C.J.
    A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
    Mol Cancer (2016) 15, 29-29. PubMed  Europe PubMed DOI  PMC  EPMC  I
    34. 2015
  34. Barlow,N., Nasser,Y., Zhao,P., Sharma,N., Guerrero-Alba,R., Edgington-Mitchell,L.E., Lieu,T., Veldhuis,N.A., Poole,D.P., Conner,J.W., Lindstrom,E., Craig,A.W., Graham,B., Vanner,S.J. and Bunnett,N.W.
    Demonstration of elevated levels of active cathepsin S in dextran sulfate sodium colitis using a new activatable probe
    Neurogastroenterol Motil (2015) 27, 1675-1680. PubMed  Europe PubMed DOI  L  I
  35. Figueiredo,J.L., Aikawa,M., Zheng,C., Aaron,J., Lax,L., Libby,P., de Lima Filho,J.L., Gruener,S., Fingerle,J., Haap,W., Hartmann,G. and Aikawa,E.
    Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease
    Am J Pathol (2015) 185, 1156-1166. PubMed  Europe PubMed DOI  I
  36. Kohl,F., Schmitz,J., Furtmann,N., Schulz-Fincke,A.C., Mertens,M.D., Kuppers,J., Benkhoff,M., Tobiasch,E., Bartz,U., Bajorath,J., Stirnberg,M. and Gutschow,M.
    Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors
    Org Biomol Chem (2015) 13, 10310-10323. PubMed  Europe PubMed DOI  I
  37. Rupanagudi,K.V., Kulkarni,O.P., Lichtnekert,J., Darisipudi,M.N., Mulay,S.R., Schott,B., Gruner,S., Haap,W., Hartmann,G. and Anders,H.J.
    Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming
    Ann Rheum Dis (2015) 74, 452-463. PubMed  Europe PubMed DOI  I
    38. 2014
  38. Battu,M.B., Chandra,A.M., Sriram,D. and Yogeeswari,P.
    Pharmacophore-based 3DQSAR and molecular docking studies to identify new non-peptidic inhibitors of cathepsin S
    Curr Med Chem (2014) 21, 1910-1921. PubMed  Europe PubMed  I
  39. Bernard,N.J.
    Connective tissue diseases. Inhibiting cathepsin S to treat SLE and lupus nephritis
    Nat Rev Rheumatol (2014) 10, 66-66. PubMed  Europe PubMed DOI  I
  40. Chua,K.C., Pietsch,M., Zhang,X., Hautmann,S., Chan,H.Y., Bruning,J.B., Gutschow,M. and Abell,A.D.
    Macrocyclic protease inhibitors with reduced peptide character
    Angew Chem Int Ed Engl (2014) 53, 7828-7831. PubMed  Europe PubMed DOI  I
  41. Jadhav,P.K., Schiffler,M.A., Gavardinas,K., Kim,E.J., Matthews,D.P., Staszak,M.A., Coffey,D.S., Shaw,B.W., Cassidy,K.C., Brier,R.A., Zhang,Y., Christie,R.M., Matter,W.F., Qing,K., Durbin,J.D., Wang,Y. and Deng,G.G.
    Discovery of cathepsin S inhibitor LY3000328 for the treatment of abdominal aortic aneurysm
    ACS Med Chem Lett (2014) 5, 1138-1142. PubMed  Europe PubMed DOI  PMC  EPMC  I
  42. Kim,M., Jeon,J., Baek,J., Choi,J., Park,E.J., Song,J., Bang,H., Suh,K.H., Kim,Y.H., Kim,J., Kim,D., Min,K.H. and Lee,K.-O.
    Synthesis of vinyl sulfone-tethered proline derivatives as highly selective cathepsin S inhibitors
    Bull Korean Chem Soc (2014) 35, 345-346. DOI  I
  43. Lafarge,J.C., Pini,M., Pelloux,V., Orasanu,G., Hartmann,G., Venteclef,N., Sulpice,T., Shi,G.P., Clement,K. and Guerre-Millo,M.
    Cathepsin S inhibition lowers blood glucose levels in mice
    Diabetologia (2014) 57, 1674-1683. PubMed  Europe PubMed DOI  I
  44. Payne,C.D., Deeg,M.A., Chan,M., Tan,L.H., LaBell,E.S., Shen,T. and DeBrota,D.J.
    Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects
    Br J Clin Pharmacol (2014) 78, 1334-1342. PubMed  Europe PubMed DOI  I
  45. Tsai,J.Y., Lee,M.J., Chang,M.D., Wang,H.C., Lin,C.C. and Huang,H.
    Effects of novel human cathepsin S inhibitors on cell migration in human cancer cells
    J Enzyme Inhib Med Chem (2014) 29, 538-546. PubMed  Europe PubMed DOI  I
    46. 2013
  46. Feth,M.P., Heyse,W., Baumgartner,B., Nagel,N., Tappertzhofen,C., Olpp,T., Jurascheck,J., Ulrich,J., Helmdach,L. and Petzoldt,C.
    From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor
    Eur J Pharm Biopharm (2013) 83, 436-448. PubMed  Europe PubMed DOI  I
  47. Hilpert,H., Mauser,H., Humm,R., Anselm,L., Kuehne,H., Hartmann,G., Gruener,S., Banner,D.W., Benz,J., Gsell,B., Kuglstatter,A., Stihle,M., Thoma,R., Sanchez,R.A., Iding,H., Wirz,B. and Haap,W.
    Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds
    J Med Chem (2013) 56, 9789-9801. PubMed  Europe PubMed DOI  I
  48. Huang,C.C., Chen,K.L., Cheung,C.H. and Chang,J.Y.
    Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase
    Free Radic Biol Med (2013) 65, 1473-1486. PubMed  Europe PubMed DOI  I
  49. Kim,M., Jeon,J., Song,J., Suh,K.H., Kim,Y.H., Min,K.H. and Lee,K.O.
    Synthesis of proline analogues as potent and selective cathepsin S inhibitors
    Bioorg Med Chem Lett (2013) 23, 3140-3144. PubMed  Europe PubMed DOI  I
  50. Pehere,A.D., Pietsch,M., Gutschow,M., Neilsen,P.M., Pedersen,D.S., Nguyen,S., Zvarec,O., Sykes,M.J., Callen,D.F. and Abell,A.D.
    Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors
    Chemistry (2013) 19, 7975-7981. PubMed  Europe PubMed DOI  I
  51. Wiener,J.J., Wickboldt,A.T., Nguyen,S., Sun,S., Rynberg,R., Rizzolio,M., Karlsson,L., Edwards,J.P. and Grice,C.A.
    Pyrazole-based arylalkyne cathepsin S inhibitors. Part III: modification of P4 region
    Bioorg Med Chem Lett (2013) 23, 1070-1074. PubMed  Europe PubMed DOI  I
  52. Xu,J., Wang,H., Ding,K., Lu,X., Li,T., Wang,J., Wang,C. and Wang,J.
    Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice
    Mediators Inflamm (2013) 2013, 187873-187873. PubMed  Europe PubMed DOI  PMC  EPMC  I
    53. 2012
  53. Chen,K.L., Chang,W.S., Cheung,C.H., Lin,C.C., Huang,C.C., Yang,Y.N., Kuo,C.P., Kuo,C.C., Chang,Y.H., Liu,K.J., Wu,C.M. and Chang,J.Y.
    Targeting cathepsin S induces tumor cell autophagy via the EGFR-Erk signaling pathway
    Cancer Lett (2012) 317, 89-98. PubMed  Europe PubMed DOI  I
  54. Frizler,M., Schmitz,J., Schulz-Fincke,A.C. and Gutschow,M.
    Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F
    J Med Chem (2012) 55, 5982-5986. PubMed  Europe PubMed DOI  I
  55. Fujii,H., Ivison,S.M., Shimizu,H., Kajiwara,R., Kariminia,A., Yan,M., Dutz,J.P. and Schultz,K.R.
    Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens
    Biol Blood Marrow Transplant (2012) 18, 546-556. PubMed  Europe PubMed DOI  I
  56. Moss,N., Xiong,Z., Burke,M., Cogan,D., Gao,D.A., Haverty,K., Heim-Riether,A., Hickey,E.R., Nagaraja,R., Netherton,M., O'Shea,K., Ramsden,P., Schwartz,R., Shih,D.T., Ward,Y., Young,E. and Zhang,Q.
    Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement
    Bioorg Med Chem Lett (2012) 22, 7189-7193. PubMed  Europe PubMed DOI  I
    57. 2011
  57. Baugh,M., Black,D., Westwood,P., Kinghorn,E., McGregor,K., Bruin,J., Hamilton,W., Dempster,M., Claxton,C., Cai,J., Bennett,J., Long,C., McKinnon,H., Vink,P., Hoed,L., Gorecka,M., Vora,K., Grant,E., Percival,M.D., Boots,A.M. and van Lierop,M.J.
    Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity
    J Autoimmun (2011) 36, 201-209. PubMed  Europe PubMed DOI  I
  58. Deschamps,K., Cromlish,W., Weicker,S., Lamontagne,S., Huszar,S.L., Gauthier,J.Y., Mudgett,J.S., Guimond,A., Romand,R., Frossard,N., Percival,M.D., Slipetz,D. and Tan,C.M.
    Genetic and pharmacological evaluation of cathepsin S in a mouse model of asthma
    Am J Respir Cell Mol Biol (2011) 45, 81-87. PubMed  Europe PubMed DOI  K  I
  59. Jiang,C., Sun,W., Zhou,X.P. and Yang,X.H.
    Cathepsin S inhibitors and the structure-activity relationship: research advances
    J Int Pharm Res (2011) 38, 182-188.  I
  60. Kerns,J.K., Nie,H., Bondinell,W., Widdowson,K.L., Yamashita,D.S., Rahman,A., Podolin,P.L., Carpenter,D.C., Jin,Q., Riflade,B., Dong,X., Nevins,N., Keller,P.M., Mitchell,L. and Tomaszek,T.
    Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent
    Bioorg Med Chem Lett (2011) 21, 4409-4415. PubMed  Europe PubMed DOI  I
  61. Lee-Dutra,A., Wiener,D.K. and Sun,S.
    Cathepsin S inhibitors: 2004 - 2010
    Expert Opin Ther Pat (2011) 21, 311-337. PubMed  Europe PubMed DOI  V  I
  62. Loser,R.
    Cathepsin S inhibitors: WO2010070615
    Expert Opin Ther Pat (2011) 21, 585-591. PubMed  Europe PubMed DOI  I
  63. Veilleux,A., Black,W.C., Gauthier,J.Y., Mellon,C., Percival,M.D., Tawa,P. and Falgueyret,J.P.
    Probing cathepsin S activity in whole blood by the activity-based probe BIL-DMK: cellular distribution in human leukocyte populations and evidence of diurnal modulation
    Anal Biochem (2011) 411, 43-49. PubMed  Europe PubMed DOI  I
    64. 2010
  64. Ameriks,M.K., Bembenek,S.D., Burdett,M.T., Choong,I.C., Edwards,J.P., Gebauer,D., Gu,Y., Karlsson,L., Purkey,H.E., Staker,B.L., Sun,S., Thurmond,R.L. and Zhu,J.
    Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors
    Bioorg Med Chem Lett (2010) 20, 4060-4064. PubMed  Europe PubMed DOI  I
  65. Cai,J., Robinson,J., Belshaw,S., Everett,K., Fradera,X., van Zeeland,M., van Berkom,L., van Rijnsbergen,P., Popplestone,L., Baugh,M., Dempster,M., Bruin,J., Hamilton,W., Kinghorn,E., Westwood,P., Kerr,J., Rankovic,Z., Arbuckle,W., Bennett,D.J., Jones,P.S., Long,C., Martin,I., Uitdehaag,J.C. and Meulemans,T.
    Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors
    Bioorg Med Chem Lett (2010) 20, 6890-6894. PubMed  Europe PubMed DOI  I
  66. Cai,J., Baugh,M., Black,D., Long,C., Jonathan Bennett,D., Dempster,M., Fradera,X., Gillespie,J., Andrews,F., Boucharens,S., Bruin,J., Cameron,K.S., Cumming,I., Hamilton,W., Jones,P.S., Kaptein,A., Kinghorn,E., Maidment,M., Martin,I., Mitchell,A., Rankovic,Z., Robinson,J., Scullion,P., Uitdehaag,J.C., Vink,P., Westwood,P., van Zeeland,M., van Berkom,L., Bastiani,M. and Meulemans,T.
    6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors
    Bioorg Med Chem Lett (2010) 20, 4350-4354. PubMed  Europe PubMed DOI  I
  67. Cai,J., Bennett,D.J., Rankovic,Z., Dempster,M., Fradera,X., Gillespie,J., Cumming,I., Finlay,W., Baugh,M., Boucharens,S., Bruin,J., Cameron,K.S., Hamilton,W., Kerr,J., Kinghorn,E., McGarry,G., Robinson,J., Scullion,P., Uitdehaag,J.C., van Zeeland,M., Potin,D., Saniere,L., Fouquet,A., Chevallier,F., Deronzier,H., Dorleans,C. and Nicolai,E.
    2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors
    Bioorg Med Chem Lett (2010) 20, 4447-4450. PubMed  Europe PubMed DOI  I
  68. Cai,J., Fradera,X., van Zeeland,M., Dempster,M., Cameron,K.S., Bennett,D.J., Robinson,J., Popplestone,L., Baugh,M., Westwood,P., Bruin,J., Hamilton,W., Kinghorn,E., Long,C. and Uitdehaag,J.C.
    4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important
    Bioorg Med Chem Lett (2010) 20, 4507-4510. PubMed  Europe PubMed DOI  I
  69. Chen,J.C., Uang,B.J., Lyu,P.C., Chang,J.Y., Liu,K.J., Kuo,C.C., Hsieh,H.P., Wang,H.C., Cheng,C.S., Chang,Y.H., Chang,M.D., Chang,W.S. and Lin,C.C.
    Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis
    J Med Chem (2010) 53, 4545-4549. PubMed  Europe PubMed DOI  I
  70. Frizler,M., Stirnberg,M., Sisay,M.T. and Gutschow,M.
    Development of nitrile-based peptidic inhibitors of cysteine cathepsins
    Curr Top Med Chem (2010) 10, 294-322. PubMed  Europe PubMed DOI  T  I
  71. Isabel,E., Bateman,K.P., Chauret,N., Cromlish,W., Desmarais,S., Duong,l.T., Falgueyret,J.P., Gauthier,J.Y., Lamontagne,S., Lau,C.K., Leger,S., LeRiche,T., Levesque,J.F., Li,C.S., Masse,F., McKay,D.J., Mellon,C., Nicoll-Griffith,D.A., Oballa,R.M., Percival,M.D., Riendeau,D., Robichaud,J., Rodan,G.A., Rodan,S.B., Seto,C., Therien,M., Truong,V.L., Wesolowski,G., Young,R.N., Zamboni,R. and Black,W.C.
    The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor
    Bioorg Med Chem Lett (2010) 20, 887-892. PubMed  Europe PubMed DOI  I
  72. Lee-Dutra,A., Wiener,D.K., Arienti,K.L., Liu,J., Mani,N., Ameriks,M.K., Axe,F.U., Gebauer,D., Desai,P.J., Nguyen,S., Randal,M., Thurmond,R.L., Sun,S., Karlsson,L., Edwards,J.P., Jones,T.K. and Grice,C.A.
    Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: Part 1
    Bioorg Med Chem Lett (2010) 20, 2370-2374. PubMed  Europe PubMed DOI  I
  73. Piovan,L., Alves,M.F.M., Juliano,L., Bromme,D., Cunha,R.L.O.R. and Andrade,L.H.
    Chemoenzymatic synthesis of organoselenium(IV) compounds and their evaluation as cysteine protease inhibitors
    J Braz Chem Soc (2010) 21, 2108-2118.  I
  74. Samokhin,A.O., Lythgo,P.A., Gauthier,J.Y., Percival,M.D. and Bromme,D.
    Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice
    J Cardiovasc Pharmacol (2010) 56, 98-105. PubMed  Europe PubMed DOI  I
  75. Wiener,D.K., Lee-Dutra,A., Bembenek,S., Nguyen,S., Thurmond,R.L., Sun,S., Karlsson,L., Grice,C.A., Jones,T.K. and Edwards,J.P.
    Thioether acetamides as P3 binding elements for tetrahydropyrido-pyrazole cathepsin S inhibitors
    Bioorg Med Chem Lett (2010) 20, 2379-2382. PubMed  Europe PubMed DOI  I
  76. Wiener,J.J., Wickboldt,A.T., Jr., Wiener,D.K., Lee-Dutra,A., Edwards,J.P., Karlsson,L., Nguyen,S., Sun,S., Jones,T.K. and Grice,C.A.
    Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors. Part 2: Modification of P3, P4, and P5 regions
    Bioorg Med Chem Lett (2010) 20, 2375-2378. PubMed  Europe PubMed DOI  I
  77. Wiener,J.J., Sun,S. and Thurmond,R.L.
    Recent advances in the design of cathepsin S inhibitors
    Curr Top Med Chem (2010) 10, 717-732. PubMed  Europe PubMed DOI  V  I
    78. 2009
  78. Ameriks,M.K., Axe,F.U., Bembenek,S.D., Edwards,J.P., Gu,Y., Karlsson,L., Randal,M., Sun,S., Thurmond,R.L. and Zhu,J.
    Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements
    Bioorg Med Chem Lett (2009) 19, 6131-6134. PubMed  Europe PubMed DOI  S  I
  79. Ameriks,M.K., Cai,H., Edwards,J.P., Gebauer,D., Gleason,E., Gu,Y., Karlsson,L., Nguyen,S., Sun,S., Thurmond,R.L. and Zhu,J.
    Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: Optimization of cellular potency
    Bioorg Med Chem Lett (2009) 19, 6135-6139. PubMed  Europe PubMed DOI  I
  80. Ayesa,S., Lindquist,C., Agback,T., Benkestock,K., Classon,B., Henderson,I., Hewitt,E., Jansson,K., Kallin,A., Sheppard,D. and Samuelsson,B.
    Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity
    Bioorg Med Chem (2009) 17, 1307-1324. PubMed  Europe PubMed DOI  I
  81. Bethel,P.A., Gerhardt,S., Jones,E.V., Kenny,P.W., Karoutchi,G.I., Morley,A.D., Oldham,K., Rankine,N., Augustin,M., Krapp,S., Simader,H. and Steinbacher,S.
    Design of selective cathepsin inhibitors
    Bioorg Med Chem Lett (2009) 19, 4622-4625. PubMed  Europe PubMed DOI  I
  82. Clark,A.K., Yip,P.K. and Malcangio,M.
    The liberation of fractalkine in the dorsal horn requires microglial cathepsin S
    J Neurosci (2009) 29, 6945-6954. PubMed  Europe PubMed DOI  PMC  EPMC  I
    83. 2008
  83. Irie,O., Ehara,T., Iwasaki,A., Yokokawa,F., Sakaki,J., Hirao,H., Kanazawa,T., Teno,N., Horiuchi,M., Umemura,I., Gunji,H., Masuya,K., Hitomi,Y., Iwasaki,G., Nonomura,K., Tanabe,K., Fukaya,H., Kosaka,T., Snell,C.R. and Hallett,A.
    Discovery of selective and nonpeptidic cathepsin S inhibitors
    Bioorg Med Chem Lett (2008) 18, 3959-3962. PubMed  Europe PubMed DOI  I
  84. Irie,O., Yokokawa,F., Ehara,T., Iwasaki,A., Iwaki,Y., Hitomi,Y., Konishi,K., Kishida,M., Toyao,A., Masuya,K., Gunji,H., Sakaki,J., Iwasaki,G., Hirao,H., Kanazawa,T., Tanabe,K., Kosaka,T., Hart,T.W. and Hallett,A.
    4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors
    Bioorg Med Chem Lett (2008) 18, 4642-4646. PubMed  Europe PubMed DOI  I
  85. Irie,O., Kosaka,T., Ehara,T., Yokokawa,F., Kanazawa,T., Hirao,H., Iwasaki,A., Sakaki,J., Teno,N., Hitomi,Y., Iwasaki,G., Fukaya,H., Nonomura,K., Tanabe,K., Koizumi,S., Uchiyama,N., Bevan,S.J., Malcangio,M., Gentry,C., Fox,A.J., Yaqoob,M., Culshaw,A.J. and Allan,H.
    Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain
    J Med Chem (2008) 51, 5502-5505. PubMed  Europe PubMed DOI  I
  86. Irie,O., Kosaka,T., Kishida,M., Sakaki,J., Masuya,K., Konishi,K., Yokokawa,F., Ehara,T., Iwasaki,A., Iwaki,Y., Hitomi,Y., Toyao,A., Gunji,H., Teno,N., Iwasaki,G., Hirao,H., Kanazawa,T., Tanabe,K., Hiestand,P.C., Malcangio,M., Fox,A.J., Bevan,S.J., Yaqoob,M., Culshaw,A.J., Hart,T.W. and Hallett,A.
    Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2
    Bioorg Med Chem Lett (2008) 18, 5280-5284. PubMed  Europe PubMed DOI  I
  87. Markt,P., McGoohan,C., Walker,B., Kirchmair,J., Feldmann,C., De Martino,G., Spitzer,G., Distinto,S., Schuster,D., Wolber,G., Laggner,C. and Langer,T.
    Discovery of novel cathepsin S inhibitors by pharmacophore-based virtual high-throughput screening
    J Chem Inf Model (2008) 48, 1693-1705. PubMed  Europe PubMed DOI  I
    88. 2007
  88. Bekkali,Y., Thomson,D.S., Betageri,R., Emmanuel,M.J., Hao,M.H., Hickey,E., Liu,W., Patel,U., Ward,Y.D., Young,E.R., Nelson,R., Kukulka,A., Brown,M.L., Crane,K., White,D., Freeman,D.M., Labadia,M.E., Wildeson,J. and Spero,D.M.
    Identification of a novel class of succinyl-nitrile-based cathepsin S inhibitors
    Bioorg Med Chem Lett (2007) 17, 2465-2469. PubMed  Europe PubMed DOI  I
  89. Chatterjee,A.K., Liu,H., Tully,D.C., Guo,J., Epple,R., Russo,R., Williams,J., Roberts,M., Tuntland,T., Chang,J., Gordon,P., Hollenbeck,T., Tumanut,C., Li,J. and Harris,J.L.
    Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S
    Bioorg Med Chem Lett (2007) 17, 2899-2903. PubMed  Europe PubMed DOI  I
  90. Clark,A.K., Yip,P.K., Grist,J., Gentry,C., Staniland,A.A., Marchand,F., Dehvari,M., Wotherspoon,G., Winter,J., Ullah,J., Bevan,S. and Malcangio,M.
    Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain
    Proc Natl Acad Sci U S A (2007) 104, 10655-10660. PubMed  Europe PubMed DOI  PMC  EPMC  I
  91. Gauthier,J.Y., Black,W.C., Courchesne,I., Cromlish,W., Desmarais,S., Houle,R., Lamontagne,S., Li,C.S., Masse,F., McKay,D.J., Ouellet,M., Robichaud,J., Truchon,J.F., Truong,V.L., Wang,Q. and Percival,M.D.
    The identification of potent, selective, and bioavailable cathepsin S inhibitors
    Bioorg Med Chem Lett (2007) 17, 4929-4933. PubMed  Europe PubMed DOI  I
  92. Inagaki,H., Tsuruoka,H., Hornsby,M., Lesley,S.A., Spraggon,G. and Ellman,J.A.
    Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode
    J Med Chem (2007) 50, 2693-2699. PubMed  Europe PubMed DOI  I
  93. Wei,J., Pio,B.A., Cai,H., Meduna,S.P., Sun,S., Gu,Y., Jiang,W., Thurmond,R.L., Karlsson,L. and Edwards,J.P.
    Pyrazole-based cathepsin S inhibitors with improved cellular potency
    Bioorg Med Chem Lett (2007) 17, 5525-5528. PubMed  Europe PubMed DOI  I
    94. 2006
  94. [YEAR:10-1-2006]Alper,P.B., Liu,H., Chatterjee,A.K., Nguyen,K.T., Tully,D.C., Tumanut,C., Li,J., Harris,J.L., Tuntland,T., Chang,J., Gordon,P., Hollenbeck,T. and Karanewsky,D.S.
    Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl
    Bioorg Med Chem Lett (10-1-2006) 16, 1486-1490. PubMed  Europe PubMed DOI  I
  95. [YEAR:28-3-2006]Desai,S.N., White,D.M., O'shea,K.M., Brown,M.L., Cywin,C.L., Spero,D.M. and Panzenbeck,M.J.
    An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity
    Eur J Pharmacol (28-3-2006) 538, 168-174. PubMed  Europe PubMed DOI  I
  96. [YEAR:1-2-2006]Grice,C.A., Tays,K., Khatuya,H., Gustin,D.J., Butler,C.R., Wei,J., Sehon,C.A., Sun,S., Gu,Y., Jiang,W., Thurmond,R.L., Karlsson,L. and Edwards,J.P.
    The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors
    Bioorg Med Chem Lett (1-2-2006) 16, 2209-2212. PubMed  Europe PubMed DOI  I
  97. Link,J.O. and Zipfel,S.
    Advances in cathepsin S inhibitor design
    Curr Opin Drug Discov Devel (2006) 9, 471-482. PubMed  Europe PubMed  T  I
  98. [YEAR:19-10-2006]Patterson,A.W., Wood,W.J., Hornsby,M., Lesley,S., Spraggon,G. and Ellman,J.A.
    Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method
    J Med Chem (19-10-2006) 49, 6298-6307. PubMed  Europe PubMed DOI  I
  99. [YEAR:27-1-2006]Tully,D.C., Liu,H., Alper,P.B., Chatterjee,A.K., Epple,R., Roberts,M.J., Williams,J.A., Nguyen,K.T., Woodmansee,D.H., Tumanut,C., Li,J., Spraggon,G., Chang,J., Tuntland,T., Harris,J.L. and Karanewsky,D.S.
    Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3
    Bioorg Med Chem Lett (27-1-2006) 16, 1975-1980. PubMed  Europe PubMed DOI  S  I
  100. [YEAR:27-7-2006]Tully,D.C., Liu,H., Chatterjee,A.K., Alper,P.B., Epple,R., Williams,J.A., Roberts,M.J., Woodmansee,D.H., Masick,B.T., Tumanut,C., Li,J., Spraggon,G., Hornsby,M., Chang,J., Tuntland,T., Hollenbeck,T., Gordon,P., Harris,J.L. and Karanewsky,D.S.
    Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers
    Bioorg Med Chem Lett (27-7-2006) 16, 5112-5117. PubMed  Europe PubMed DOI  I
  101. [YEAR:27-7-2006]Tully,D.C., Liu,H., Chatterjee,A.K., Alper,P.B., Williams,J.A., Roberts,M.J., Mutnick,D., Woodmansee,D.H., Hollenbeck,T., Gordon,P., Chang,J., Tuntland,T., Tumanut,C., Li,J., Harris,J.L. and Karanewsky,D.S.
    Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors
    Bioorg Med Chem Lett (27-7-2006) 16, 5107-5111. PubMed  Europe PubMed DOI  I
    102. 2005
  102. [YEAR:15-3-2005]Gustin,D.J., Sehon,C.A., Wei,J., Cai,H., Meduna,S.P., Khatuya,H., Sun,S., Gu,Y., Jiang,W., Thurmond,R.L., Karlsson,L. and Edwards,J.P.
    Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors
    Bioorg Med Chem Lett (15-3-2005) 15, 1687-1691. PubMed  Europe PubMed DOI  I
  103. [YEAR:15-11-2005]Liu,H., Tully,D.C., Epple,R., Bursulaya,B., Li,J., Harris,J.L., Williams,J.A., Russo,R., Tumanut,C., Roberts,M.J., Alper,P.B., He,Y. and Karanewsky,D.S.
    Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1
    Bioorg Med Chem Lett (15-11-2005) 15, 4979-4984. PubMed  Europe PubMed DOI  I
  104. Thurmond,R.L., Sun,S., Karlsson,L. and Edwards,J.P.
    Cathepsin S inhibitors as novel immunomodulators
    Curr Opin Investig Drugs (2005) 6, 473-482. PubMed  Europe PubMed  I
  105. Yasuda,Y., Kaleta,J. and Bromme,D.
    The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics
    Adv Drug Deliv Rev (2005) 57, 973-993. PubMed  Europe PubMed DOI  T  I
    106. 2004
  106. Marquis,R.W.
    Inhibition of the cysteine protease cathepsin K (EC 3.4.22.38)
    Annu Rep Med Chem (2004) 39, 79-98. DOI  V  I
  107. [YEAR:23-9-2004]Thurmond,R.L., Beavers,M.P., Cai,H., Meduna,S.P., Gustin,D.J., Sun,S., Almond,H.J., Karlsson,L. and Edwards,J.P.
    Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S
    J Med Chem (23-9-2004) 47, 4799-4801. PubMed  Europe PubMed DOI  I
  108. [YEAR:17-10-2004]Thurmond,R.L., Sun,S., Sehon,C.A., Baker,S.M., Cai,H., Gu,Y., Jiang,W., Riley,J.P., Williams,K.N., Edwards,J.P. and Karlsson,L.
    Identification of a potent and selective noncovalent cathepsin S inhibitor
    J Pharmacol Exp Ther (17-10-2004) 308, 268-276. PubMed  Europe PubMed DOI  I
    109. 2002
  109. Saegusa,K., Ishimaru,N., Yanagi,K., Arakaki,R., Ogawa,K., Saito,I., Katunuma,N. and Hayashi,Y.
    Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity
    J Clin Invest (2002) 110, 361-369. PubMed  Europe PubMed DOI  PMC  EPMC  I
  110. [YEAR:5-12-2002]Ward,Y.D., Thomson,D.S., Frye,L.L., Cywin,C.L., Morwick,T., Emmanuel,M.J., Zindell,R., McNeil,D., Bekkali,Y., Giradot,M., Hrapchak,M., DeTuri,M., Crane,K., White,D., Pav,S., Wang,Y., Hao,M.H., Grygon,C.A., Labadia,M.E., Freeman,D.M., Davidson,W., Hopkins,J.L., Brown,M.L., Spero,D.M. and Giradot,M.
    Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors
    J Med Chem (5-12-2002) 45, 5471-5482. PubMed  Europe PubMed DOI  I
    111. 2000
  111. [YEAR:28-8-2000]Walker,B., Lynas,J.F., Meighan,M.A. and Bromme,D.
    Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S
    Biochem Biophys Res Commun (28-8-2000) 275, 401-405. PubMed  Europe PubMed DOI  I
    112. 1998
  112. McGrath,M.E., Palmer,J.T., Bromme,D. and Somoza,J.R.
    Crystal structure of human cathepsin S
    Protein Sci (1998) 7, 1294-1302. PubMed  Europe PubMed DOI  PMC  EPMC  S  I
    113. 1994
  113. Gour-Salin,B.J., Lachance,P., Bonneau,P.R., Storer,A.C., Kirschke,H. and Bromme,D.
    E-64 analogs as inhibitors of cathepsin L and cathepsin S: importance of the S2-P2 interactions for potency and selectivity
    Bioorg Chem (1994) 22, 227-241.  I
    114. 1993
  114. Shaw,E., Mohanty,S., Colic,A., Stoka,V. and Turk,V.
    The affinity-labelling of cathepsin S with peptidyl diazomethyl ketones. Comparison with the inhibition of cathepsin L and calpain
    FEBS Lett (1993) 334, 340-342. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use